We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 10 of 106 for:    fibromyalgia | Recruiting, Not yet recruiting, Available Studies | Interventional Studies

Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia

This study is currently recruiting participants.
Verified October 2017 by Aptinyx
Sponsor:
ClinicalTrials.gov Identifier:
NCT03249103
First Posted: August 15, 2017
Last Update Posted: October 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
inVentiv Health Clinical
Information provided by (Responsible Party):
Aptinyx
  Purpose
The primary objective is to determine whether daily dosing with NYX-2925 changes markers of central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain, and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy (H-MRS) in fibromyalgia subjects on active drug versus placebo.

Condition Intervention Phase
Fibromyalgia Drug: NYX-2925 Drug: Placebo oral capsule Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
All subjects will receive NYX-2925 Low Dose, NYX-2925 High Dose, and placebo PO QD for 2 week treatment periods, then go into Follow-up for 1 week.
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia

Resource links provided by NLM:


Further study details as provided by Aptinyx:

Primary Outcome Measures:
  • Changes in markers of central pain processing as measured by functional magnetic resonance imaging. [ Time Frame: Screening through Week 6 ]

Secondary Outcome Measures:
  • Evaluate safety as measured by the incidence of adverse events [ Time Frame: Screening through Week 7 ]
  • Evaluate the safety as measure by the change in vital sign measurements [ Time Frame: Screening through Week 7 ]
  • Evaluate the changes in clinical laboratory test results [ Time Frame: Screening through Week 7 ]
  • Evaluate the changes in electrocardiogram results [ Time Frame: Screening through Week 7 ]
  • Evaluate the changes in physical examination findings [ Time Frame: Screening through Week 7 ]
  • Evaluating suicidal ideation and behavior as measure by the Columbia-Suicide Severity Rating Scale [ Time Frame: Screening through Week 7 ]

Estimated Enrollment: 24
Actual Study Start Date: August 14, 2017
Estimated Study Completion Date: July 30, 2018
Estimated Primary Completion Date: March 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Up to 24 subjects will receive Placebo
Drug: Placebo oral capsule
Matching placebo capsules.
Experimental: NYX-2925 High Dose
Up to 24 subjects will receive High Dose of NYX-2925
Drug: NYX-2925
NYX-2925 is a new molecular entity that modulates the N-methyl-D-aspartate receptor (NMDAR).
Experimental: Low Dose
Up to 24 subjects will receive Low Dose of NYX-2925
Drug: NYX-2925
NYX-2925 is a new molecular entity that modulates the N-methyl-D-aspartate receptor (NMDAR).

Detailed Description:

This is a single-blind, exploratory, placebo-controlled, pilot study to assess the efficacy and safety of daily oral NYX-2925 in fibromyalgia subjects. The study will include a screening period (up to 30 days), a placebo period, an active treatment period with, and a follow-up period as follows:

  • Placebo PO Every Day (QD) for 2 weeks
  • NYX-2925 PO QD for 2 weeks (2x)
  • Follow-up for 1 week

Eligible subjects will receive MRIs during the screening period, during the placebo period, during the NYX-2925 PO QD period. Safety assessments will be conducted and adverse events will be collected during the study. Daily pain scores and other fibromyalgia scales will be collected during the study. Daily pain scores and other fibromyalgia scales will be collected for exploratory analysis. During the follow-up period, an optional MRI will be completed for consenting subjects in order to evaluate duration of effect.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects meets the 2010 American College of Rheumatology (ACR) criteria for fibromyalgia.
  2. Self-reported clinical pain ≥ 4 and on the Numeric Pain Rating Scale (NPRS) at screening and baseline.
  3. Subject receives and agrees to remain on their stable fibromyalgia treatment plan established at least 14 days prior to dosing.
  4. Subject agrees to use only non-steroidal anti-inflammatory (NSAID) or acetaminophen treatment as needed for breakthrough pain, and/or, zopiclone, zolpidem, zaleplon, or eszopiclone for sleep (if needed).
  5. Right handed.
  6. Calculates creatinine clearance ≥ 60 mL/minute.
  7. Female subjects of child bearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (e.g., surgical sterilization, oral or parenteral contraceptives, intrauterine device that is considered safe for MRI procedures, barrier [condom with spermicide]) and who do not plan to become pregnant, breastfeed, or donate ova during the course of the study and for 28 days after the final administration of investigational product.
  8. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.

Exclusion Criteria:

  1. Current or expected use of opioid or narcotic analgesics, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, gabapentinoids, topiramate, anticonvulsants, benzodiazepines, and sedatives, or hypnotics.
  2. Unstable doses of allowed antidepressants or muscle relaxants. Use of NSAIDs or acetaminophen 24 hours prior to imaging procedures is prohibited.
  3. Pain due to concurrent disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, or other chronic widespread pain condition(s) that may confound fibromyalgia pain.
  4. Untreated endocrine disorder that may confound fibromyalgia assessments.
  5. Psychiatric or cognitive disorder (e.g., current schizophrenia, severe depression, suicidal ideation, dementia, etc.).
  6. Clinically significant alcohol or other substance abuse within the last 2 years.
  7. Positive screen for medically inappropriate or illegal use of drugs of abuse.
  8. Current treatment with medications such as ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
  9. History of allergy, sensitivity, or intolerance to medications such as ketamine, amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
  10. Women, who are pregnant, breast feeding, or planning to become pregnant or donate ova during the course of the study and for 28 days after the final administration of investigational product.
  11. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or history of seizures, epilepsy, or strokes.
  12. Contraindications to fMRI procedures. These may include but are not limited to: surgical clips, surgical staples, metal implants, and certain metallic dental material.
  13. Current or habitual use (within the last 12 months) of artificial nails, nails enhancements, or nail extensions that cover any portion of either thumbnail.
  14. Abnormal laboratory results, medical history, or concurrent conditions that would preclude safe study participation, or interfere with study procedures/assessments.
  15. Impaired liver function.
  16. Known history of significant heart condition or high blood pressure.
  17. Current evidence of dysplasia or history of cancer malignancy (including lymphoma and leukemia) in the last 5 years.
  18. Human immunodeficiency virus (HIV) infection, hepatitis, or other ongoing infectious disease.
  19. History of severe kidney or liver impairment.
  20. History of migraine.
  21. History of lower limb vascular surgery or current lower limb vascular dysfunction.
  22. Received an investigational drug or device within 30 days of dosing.
  23. Previous treatment with NYX-2925.
  24. Resting heart rate < 45 or ≥ 95 beats per minute.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03249103


Contacts
Contact: Stephen Sainati, MD, PHD 847 871 0377 ext 1 clinicalstudies@aptinyx.com
Contact: Mary Suh, BS, MSN 847 871 0377 ext 141

Locations
United States, Michigan
Aptinyx Clinical Site Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Ohio
Aptinyx Clinical Site Recruiting
Cincinnati, Ohio, United States, 45220
Sponsors and Collaborators
Aptinyx
inVentiv Health Clinical
  More Information

Responsible Party: Aptinyx
ClinicalTrials.gov Identifier: NCT03249103     History of Changes
Other Study ID Numbers: NYX-2925-2002
First Submitted: August 2, 2017
First Posted: August 15, 2017
Last Update Posted: October 5, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Aptinyx:
Fibromyalgia

Additional relevant MeSH terms:
Fibromyalgia
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases